• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

下调激肽释放酶相关肽 5(KLK5)在乳腺癌患者中的表达:用于鉴别诊断乳腺病变的生物标志物。

Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.

机构信息

Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece.

出版信息

Clin Proteomics. 2011 May 31;8(1):5. doi: 10.1186/1559-0275-8-5.

DOI:10.1186/1559-0275-8-5
PMID:21906360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3167201/
Abstract

BACKGROUND

Kallikrein-related peptidase 5 (KLK5) is a secreted trypsin-like protease of the KLK family, encoded by the KLK5 gene. KLK5 has been found to cleave various extracellular matrix components, as well as to activate several other KLK proteases, triggering the stimulation of tissue microenvironment proteolytic cascades.

MATERIAL AND METHODS

KLK5 expression levels were quantified in 102 cancerous and benign breast tissue specimens, obtained by randomly chosen patients, using RT-qPCR assay. Subsequently, advanced biostatistics were applied in order to analyze the KLK5 expression profile in the two patients' cohorts and also to evaluate its clinical significance for the discrimination of breast tumors.

RESULTS

A statistically significant (p < 0.001) down-regulation of the KLK5 expression levels were observed in the malignant specimens compared to the benign ones. Logistic regression and ROC curve analysis revealed the significant (p < 0.001) and the independent (p < 0.001) value of the KLK5 expression quantification, for the discrimination of the malignant from the benign mammary gland biopsies. Moreover, KLK5 expression levels correlate with the pre-menopausal status (p < 0.005) as well as the ER-negative staining (p = 0.028) of women with breast cancer.

CONCLUSIONS

The quantification of KLK5 expression in breast tissue biopsies may be considered as a novel and independent biomarker for the differential diagnosis between malignant and benign tumors of the mammary gland.

摘要

背景

激肽释放酶相关肽酶 5(KLK5)是 KLK 家族的一种分泌型胰蛋白酶样蛋白酶,由 KLK5 基因编码。KLK5 已被发现可切割各种细胞外基质成分,并激活其他几种 KLK 蛋白酶,从而触发组织微环境蛋白水解级联的刺激。

材料与方法

使用 RT-qPCR 检测随机选择的 102 例癌性和良性乳腺组织标本中的 KLK5 表达水平。随后,应用高级生物统计学方法分析两个患者队列中的 KLK5 表达谱,并评估其对乳腺癌鉴别诊断的临床意义。

结果

与良性标本相比,恶性标本中 KLK5 表达水平存在统计学显著(p < 0.001)下调。逻辑回归和 ROC 曲线分析显示 KLK5 表达定量对恶性与良性乳腺活检的鉴别具有显著(p < 0.001)和独立(p < 0.001)的价值。此外,KLK5 表达水平与女性乳腺癌的绝经前状态(p < 0.005)以及 ER 阴性染色(p = 0.028)相关。

结论

在乳腺组织活检中定量 KLK5 表达可被视为鉴别乳腺良恶性肿瘤的一种新的独立生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/3945ead1e755/1559-0275-8-5-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/633fcaa820d5/1559-0275-8-5-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/8e4761848946/1559-0275-8-5-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/3945ead1e755/1559-0275-8-5-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/633fcaa820d5/1559-0275-8-5-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/8e4761848946/1559-0275-8-5-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/3167201/3945ead1e755/1559-0275-8-5-3.jpg

相似文献

1
Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.下调激肽释放酶相关肽 5(KLK5)在乳腺癌患者中的表达:用于鉴别诊断乳腺病变的生物标志物。
Clin Proteomics. 2011 May 31;8(1):5. doi: 10.1186/1559-0275-8-5.
2
Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.KLK7 mRNA 表达对晚期高级别浆液性卵巢癌的预后价值。
J Ovarian Res. 2020 Oct 21;13(1):125. doi: 10.1186/s13048-020-00725-5.
3
Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues.
Urology. 2002 Oct;60(4):714-8. doi: 10.1016/s0090-4295(02)01811-3.
4
Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.通过免疫组织化学和酶联免疫吸附测定法评估晚期卵巢癌患者肿瘤组织中激肽释放酶相关肽酶5(KLK5)蛋白表达:与临床结局的相关性
Am J Cancer Res. 2015 Dec 15;6(1):61-70. eCollection 2016.
5
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer.激肽释放酶基因5剪接变体2是乳腺癌和卵巢癌的一种新生物标志物。
Tumour Biol. 2004 Sep-Dec;25(5-6):221-7. doi: 10.1159/000081384.
6
Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence.揭示激肽释放酶相关肽酶 5(KLK5)mRNA 表达在结直肠腺瘤-癌序列中的临床影响。
Clin Chem Lab Med. 2019 Jul 26;57(8):1251-1260. doi: 10.1515/cclm-2018-1010.
7
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.人激肽释放酶5:卵巢癌患者中一种引发体液反应的有趣新型生物标志物。
Int J Gynecol Cancer. 2009 Aug;19(6):1015-21. doi: 10.1111/IGC.0b013e3181ab597f.
8
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.激肽释放酶5和激肽释放酶7信使核糖核酸在乳腺恶性肿瘤中的平行低表达。
Cancer Sci. 2009 Apr;100(4):601-7. doi: 10.1111/j.1349-7006.2009.01090.x.
9
Expression and clinical significance of KLK5-8 in endometrial cancer.KLK5 - 8在子宫内膜癌中的表达及临床意义
Am J Transl Res. 2019 Jul 15;11(7):4180-4191. eCollection 2019.
10
Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer.激肽释放酶相关肽酶5在乳腺癌中诱导miRNA介导的抗癌途径。
Oncoscience. 2014 Oct 24;1(11):709-24. doi: 10.18632/oncoscience.91. eCollection 2014.

引用本文的文献

1
Bioinformatics analysis of human kallikrein 5 () expression in metaplastic triple-negative breast cancer.人组织激肽释放酶5()在化生性三阴性乳腺癌中表达的生物信息学分析
Cancer Innov. 2023 Oct 15;2(5):376-390. doi: 10.1002/cai2.96. eCollection 2023 Oct.
2
Clinical significance of kallikrein 5 as a novel prognostic biomarker in gastric adenocarcinoma.激肽释放酶 5 作为一种新型预后生物标志物在胃腺癌中的临床意义。
J Clin Lab Anal. 2021 Oct;35(10):e23958. doi: 10.1002/jcla.23958. Epub 2021 Sep 12.
3
Search for Non-Protein Protease Inhibitors Constituted with an Indole and Acetylene Core.

本文引用的文献

1
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.循环生物标志物组织激肽释放酶相关肽酶 KLK5 影响卵巢癌患者的生存。
Ann Oncol. 2011 Aug;22(8):1783-90. doi: 10.1093/annonc/mdq701. Epub 2011 Jan 27.
2
Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues.定量表达分析及新型人激肽释放酶相关肽酶 14 基因(KLK14)在良恶性乳腺组织中的研究。
Thromb Haemost. 2011 Jan;105(1):131-7. doi: 10.1160/TH10-02-0092. Epub 2010 Nov 5.
3
Cancer statistics, 2010.
搜索以吲哚和乙炔核心构成的非蛋白蛋白酶抑制剂。
Molecules. 2021 Jun 23;26(13):3817. doi: 10.3390/molecules26133817.
4
Proteases are Modulated by Fascin in Oral Cancer Invasion.在口腔癌侵袭过程中,蛋白酶受肌动蛋白丝交联蛋白调控。
J Cancer Prev. 2018 Sep;23(3):141-146. doi: 10.15430/JCP.2018.23.3.141. Epub 2018 Sep 30.
5
Non-coding RNAs profiling in head and neck cancers.头颈部癌症中的非编码RNA分析
NPJ Genom Med. 2016 Jan 13;1:15004. doi: 10.1038/npjgenmed.2015.4. eCollection 2016.
6
Transcriptome profiling of cancer and normal tissues from cervical squamous cancer patients by deep sequencing.通过深度测序对宫颈鳞癌患者的癌组织和正常组织进行转录组分析。
Mol Med Rep. 2017 Aug;16(2):2075-2088. doi: 10.3892/mmr.2017.6855. Epub 2017 Jun 23.
7
Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer.激肽释放酶相关肽酶5在乳腺癌中诱导miRNA介导的抗癌途径。
Oncoscience. 2014 Oct 24;1(11):709-24. doi: 10.18632/oncoscience.91. eCollection 2014.
8
Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer.激肽释放酶基因 10 的过表达是预测胃癌不良预后的生物标志物。
World J Gastroenterol. 2013 Dec 28;19(48):9425-31. doi: 10.3748/wjg.v19.i48.9425.
9
Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.用化疗药物表柔比星、多西他赛和甲氨蝶呤处理乳腺癌细胞后,激肽释放酶相关肽酶基因KLK4、KLK5和KLK14的表达模式发生显著改变。
Tumour Biol. 2013 Feb;34(1):369-78. doi: 10.1007/s13277-012-0558-1. Epub 2012 Oct 20.
10
Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer.循环 microRNA-92a 和 microRNA-21 作为原发性乳腺癌新型微创生物标志物。
J Cancer Res Clin Oncol. 2013 Feb;139(2):223-9. doi: 10.1007/s00432-012-1315-y. Epub 2012 Sep 30.
癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
4
Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.激肽释放酶相关肽酶基因作为人类恶性肿瘤预后和监测的有希望的生物标志物。
Biol Chem. 2010 May;391(5):505-11. doi: 10.1515/BC.2010.056.
5
Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier.激肽释放酶相关肽酶:癌症中的蛋白水解和信号转导,新前沿。
Biol Chem. 2010 Apr;391(4):299-310. doi: 10.1515/BC.2010.038.
6
Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.激肽释放酶相关肽酶在人类恶性肿瘤中的预后价值和生物学作用。
Future Oncol. 2010 Feb;6(2):269-85. doi: 10.2217/fon.09.149.
7
KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.KLK5 基因表达在雄激素非依赖性前列腺癌细胞经化疗药物多西他赛和米托蒽醌处理后严重上调。
Biol Chem. 2010 Apr;391(4):467-74. doi: 10.1515/BC.2010.026.
8
Functional roles of human kallikrein-related peptidases.人激肽释放酶相关肽酶的功能作用。
J Biol Chem. 2009 Nov 27;284(48):32989-94. doi: 10.1074/jbc.R109.027946. Epub 2009 Oct 9.
9
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.激肽释放酶5和激肽释放酶7信使核糖核酸在乳腺恶性肿瘤中的平行低表达。
Cancer Sci. 2009 Apr;100(4):601-7. doi: 10.1111/j.1349-7006.2009.01090.x.
10
The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.激肽释放酶相关肽酶在结直肠癌中作为辅助预后标志物的应用。
Br J Cancer. 2009 May 19;100(10):1659-65. doi: 10.1038/sj.bjc.6605033. Epub 2009 Apr 14.